Back to Feed
ClinicalTrials.gov|Clinical Trial

Stem Cell Mobilization and Apheresis for Life-threatening Blood Disorders

St. Jude Children's Research Hospital

Abstract

The purpose of this study is to investigate mobilization and collection of HSPCs in patients with bone marrow failure syndromes (BMFS) using granulocyte-colony stimulating factor (otherwise known as Filgrastim) with plerixafor to demonstrate safety and feasibility of collecting HSPCs to advance gene therapy. Primary objective: \- To characterize the safety of Filgrastim plus plerixafor in participants with bone marrow failure syndromes as determined by the incidence of adverse events (AEs). Secondary Objectives: * To characterize the feasibility of HSPC mobilization using Filgrastim plus plerixafor as determined by peripheral blood CD34+ counts. * To measure the mobilization effects of Filgrastim plus plerixafor in the peripheral blood in participants as determined by peak peripheral blood CD34+ counts. * To estimate efficacy of Filgrastim plus plerixafor for HSPC mobilization and apheresis collection in participants as determined by the yield of CD34+ cells (CD34+ cells/kg). Phase: PHASE1 Status: NOT_YET_RECRUITING Conditions: Bone Marrow Failure Syndrome Interventions: Filgrastim; Plerixafor; Leukapheresis

Keywords

Bone Marrow Failure Syndrome
Stem Cell Mobilization and Apheresis for Life-threatening Blood Disorders | StemCell Pulse | StemCell Pulse